Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30929475 | 0.89 | F2 (0.46) | F2F7F3KDM5AKDM4C | |
| SCHEMBL30929434 | 0.89 | BRD4 (0.46) | F2F7F3PREPGRIN2B | |
| SCHEMBL30929415 | 0.83 | F2 (0.44) | F2F7F3PREPCYP3A4 | |
| SCHEMBL30929459 | 0.82 | F2 (0.41) | F2F7F3PREPBRD4 | |
| SCHEMBL30929456 | 0.82 | F2 (0.41) | F2F7F3PREPBRD4 | |
| SCHEMBL30929437 | 0.80 | F2 (0.42) | F2F7F3PREPBRD4 | |
| SCHEMBL30929423 | 0.79 | BRD4 (0.44) | F2F7F3PREPCYP3A4 | |
| SCHEMBL30929478 | 0.79 | F2 (0.41) | F2F7F3PREPCCNT1 | |
| SCHEMBL30929417 | 0.79 | F2 (0.41) | F2F7F3PREPCCNT1 | |
| SCHEMBL30929453 | 0.78 | F2 (0.40) | F2F7F3PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626891-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | Omeros Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024118840-A1 | FUSED PYRIMIDINES AS MASP-2 INHIBITORS | OMEROS CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228499-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, SPINT2, SERPINB1 | F2 107/4885F7 1393/4885F3 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.